FDA Clearances Put MammoScreen 5 and Heartvue.Proton Into Routine Workflow
New FDA clearances are pushing imaging AI from pilot use into everyday mammography and cardiac MRI workflows, with governance now central to adoption.
What is this trend?
FDA clearances for MammoScreen 5 and Heartvue.Proton show governed AI moving into routine mammography and cardiac MRI workflows, where version control and validation now matter as much as model performance.
- MammoScreen 5 is cleared for adjunctive, radiologist-in-the-loop mammogram interpretation.
- Heartvue.Proton adds cloud viewing, post-processing, and quantitative cardiac MRI analysis.
- FDA review is shifting from model novelty to workflow fit, update governance, and post-market control.
- Predetermined Change Control Plans are becoming a key advantage for regulated AI vendors.
What’s the latest?
Therapixel’s MammoScreen 5 and Heartvue.Proton pushed governed AI deeper into routine imaging workflows this week.
How it developed
- Reimbursement, real-world evidence, and workflow impact reshape device competition
- Clinical AI Is Shifting From Model Performance to Regulated Workflow Impact
Go deeper
Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.
If you operate in this industry

AI and Medicine: Who’s the Doctor?
An interview on evidence, safeguards and physician oversight in AI’s impact on clinical outcomes.
HPCwire AIwire · News
Read →From Transparency to Defensibility: The Standard Mid–Revenue Cycle AI Requires
An explainer on how mid-revenue cycle AI requires defensible recommendations, governance, and traceable evidence.
Fierce Healthcare · News
Read →
AI and Medicine: Who’s the Doctor?
An interview on clinical AI validation, patient outcomes, safety controls, and physician oversight.
QCwire · News
Read →If you sell into this industry
The Big Challenge for AI in Healthcare Comes After Approval - MedCity News
An analysis of post-approval AI oversight, covering real-world performance drift and regulated change control.
MedCity News · News
Read →FDA-Cleared AI Devices: Where They Work in Hospitals
An analysis of where cleared hospital AI improves workflows and outcomes—and where evidence remains limited.
Intelligent Living · News
Read →AI biosensors for antimicrobial resistance need claim-specific validation,
An analysis of claim-specific validation and lifecycle controls for regulated AI antimicrobial-resistance biosensors.
Bioengineer.org · News
Read →If you invest in this industry

Enterprise Imaging IT Market worth $4.59 billion by 2031 - Exclusive Report by MarketsandMarkets™
A market forecast on how AI-enabled, cloud-based imaging platforms are reshaping enterprise clinical workflows.
PR Newswire - Consumer Technology · News
Read →
Enterprise Imaging IT Market worth $4.59 billion by 2031 - Exclusive Report by MarketsandMarkets™
A market forecast on enterprise imaging growth, AI-enabled workflows, and regulatory and interoperability barriers.
PR Newswire - Business Technology · News
Read →